戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                                       Better postremission alternative therapies are especially neede
2 tment cytogenetics in risk stratification of postremission AML therapy.
3        A comparison was made of 3 aggressive postremission approaches for children and adolescents wi
4 relapse rate or remission duration in either postremission arm.
5                                    The three postremission arms remain coded.
6  post-transplant, (2) portray other forms of postremission cellular therapies, including the role of
7          The most important component of the postremission chemotherapy continues to be several cours
8 imal dose, schedule, and number of cycles of postremission chemotherapy for most patients are not kno
9  conventional high-dose cytarabine (HDAC) as postremission chemotherapy in younger patients with acut
10  (64%) of 11 patients who received intensive postremission chemotherapy with high-dose cytarabine (at
11 ted timing of induction therapy and compared postremission chemotherapy with marrow transplantation i
12                                      Second, postremission chemotherapy with or without hematopoietic
13 ete remission (CR) relapse with conventional postremission chemotherapy.
14                                              Postremission consolidation chemotherapy with either pla
15 nia in patients with AML receiving intensive postremission consolidation with AZQ and mitoxantrone.
16                       The data indicate that postremission consolidation with cytarabine before allog
17 oxic, affording an important opportunity for postremission counseling and referrals to fertility spec
18 ) at the time of diagnosis, (e) and a higher postremission cytarabine dose (P < 0.001).
19 ated mortality was 3%, and there were only 2 postremission deaths.
20 detection of minimal residual disease at the postremission induction period by immunologic methods ar
21                                  The type of postremission intensification remained significant for D
22           Blina was given as replacement for postremission intensive chemotherapy to patients with ch
23                     Our results suggest that postremission interventions should be targeted toward pa
24                                              Postremission maintenance therapy that prolongs MRD nega
25  with AML in remission and contemplate using postremission maintenance.
26 is higher-dose therapy had no benefit in the postremission management of older patients with de novo
27  a human AML cell line (HL-60), we modeled a postremission marrow with minimal residual disease and s
28 DAC induction and consolidation had the best postremission outcomes; however, the proportion of CR pa
29                                        Among postremission patients, survival from CR varied signific
30 benefit to including this combination in the postremission phase of AML.
31 patients (18%) refused to participate in the postremission phase of this study.
32                                       In the postremission phase, limiting cumulative marrow suppress
33  superior long-term survival irrespective of postremission regimen received (allogeneic BMT, 70% +/-
34                                      These 2 postremission regimens produced similar outcomes.
35 ly diagnosed acute lymphoblastic leukemia to postremission regimens that included high-dose methotrex
36 of eight patients with t(9; 11) who received postremission regimens with cytarabine at a dose of 100
37 lopment of new therapeutic strategies in the postremission state.
38                                              Postremission stem cell transplantation should be consid
39 HCT) and prolonged chemotherapy are standard postremission strategies for adult acute lymphoblastic l
40                                      Various postremission strategies have been explored to eliminate
41 lenomegaly predicts a lower CR rate, and the postremission strategies of either four cycles of I/HDAC
42 y of response after chemotherapy and to plan postremission strategies that are, therefore, driven by
43 d treatments that could be incorporated into postremission strategies to improve survival for adults
44  bone marrow transplantation is an effective postremission strategy for patients with acute myelogeno
45                                    The ideal postremission strategy in intermediate-risk acute myeloi
46 c markers in guiding chemotherapy choice and postremission strategy, as well as the utility of target
47                                              Postremission survival was 56% in patients randomized to
48  basis for prospective comparison with other postremission therapies considered standard in the manag
49                                              Postremission therapies with reduced toxicities are urge
50 re nuanced selection of patients for optimal postremission therapies.
51 ld in a clinical trial comparing 3 intensive postremission therapies: intensive chemotherapy, autolog
52 00 mg/m2 (2 patients) or who did not receive postremission therapy (2 patients) have relapsed.
53 ose cytarabine (HDAC) for both induction and postremission therapy for acute myeloid leukemia (AML) p
54  establish the role of vaccination as viable postremission therapy for acute myeloid leukemia.
55            The choice of either induction or postremission therapy for adults with acute myeloid leuk
56                                  The optimal postremission therapy for adults with ALL remains unclea
57                   AlloSCT is the most potent postremission therapy for AML and is particularly active
58 e afforded by allogeneic BMT administered as postremission therapy for AML.
59 nisone was used as the corticosteroid during postremission therapy from 1987 to 1991, and dexamethaso
60     Patients who underwent allogeneic SCT as postremission therapy had longer survival than patients
61 neic stem cell transplantation (alloHSCT) as postremission therapy has an important role in reducing
62 as concurrent gene mutations, with regard to postremission therapy in 323 patients with FLT3-ITD-posi
63        Evaluate the outcome of induction and postremission therapy in adults younger than 60 years wi
64  risk stratification and might help to guide postremission therapy in NPM1-mutated AML.
65                                              Postremission therapy in patients with acute myeloid leu
66 lloHSCT) is considered the preferred type of postremission therapy in poor- and very-poor-risk AML, t
67  is now referred to you for consideration of postremission therapy in the setting of high-risk acute
68                                        After postremission therapy including intensive chemotherapy (
69                                  The optimal postremission therapy of acute myeloid leukemia (AML) in
70                 We designed a trial in which postremission therapy of young patients with de novo acu
71 mon HLA type) and presents for discussion of postremission therapy options.
72                                   Aggressive postremission therapy or the use of hematopoietic growth
73                         Although the optimal postremission therapy remains to be determined, the high
74 erapy followed by 120 weeks of risk-assigned postremission therapy that included reinduction treatmen
75 atment, and the addition of dexamethasone to postremission therapy to increase the proportion of even
76 ceiving intensive timing irrespective of the postremission therapy to which they were allocated.
77               For the entire patient cohort, postremission therapy was an independent factor for OS (
78                This was followed by cyclical postremission therapy with high-dose cytarabine/etoposid
79 (16) and 49 adults with t(8;21), assigned to postremission therapy with repetitive cycles of higher d
80 apy, we assessed the value of azacitidine as postremission therapy with respect to disease-free survi
81 erved to identify subgroups for risk-adapted postremission therapy, but the initial treatment approac
82  expanded use of arsenic trioxide in APL for postremission therapy, in conjunction with transplantati
83                           Despite the use of postremission therapy, less than half of patients with A
84 tely, the currently available modalities for postremission therapy, namely chemotherapy, have proven
85 cribe the implications for AML diagnosis and postremission therapy.
86 atched to patients who received conventional postremission therapy.
87 nors may be considered for allogeneic SCT as postremission therapy.
88 improve risk stratification and selection of postremission therapy.
89  for t(9; 11) patients who receive intensive postremission therapy.
90                         Despite an increased postremission toxic mortality (3 years: 6.6% v. 4.1%; Hz
91                              Here, we review postremission transplantation strategies using either au
92 for the alloSCT and 46% for the conventional postremission treatment group (P = .037; log-rank test).
93                                              Postremission treatment was the same for all arms.
94 ved retinoic acid (RA) induction followed by postremission treatment with chemotherapy, RA, and biolo
95       All patients were randomly assigned to postremission treatment with standard-, intermediate-, o
96 romal recovery), and recurrence (new episode postremission) were also assessed.
97                                   During the postremission year, children of early-remitting mothers